AstraZeneca taps AI for drug discovery in deal with Berg

LONDON (Reuters) - AstraZeneca has forged a research collaboration with Boston-based Berg, a specialist in artificial intelligence for drug hunting, in the latest sign of big pharma's interest in using supercomputers for drug discovery.